BR0115995A - Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina - Google Patents

Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina

Info

Publication number
BR0115995A
BR0115995A BR0115995-0A BR0115995A BR0115995A BR 0115995 A BR0115995 A BR 0115995A BR 0115995 A BR0115995 A BR 0115995A BR 0115995 A BR0115995 A BR 0115995A
Authority
BR
Brazil
Prior art keywords
pyrimidines
pharmaceutical formulation
calcium antagonists
prostaglandin
treatment
Prior art date
Application number
BR0115995-0A
Other languages
English (en)
Inventor
Hans-Michael Eggenweiler
Volker Euermann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10063224A external-priority patent/DE10063224A1/de
Priority claimed from DE2000163882 external-priority patent/DE10063882A1/de
Priority claimed from DE2000164993 external-priority patent/DE10064993A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0115995A publication Critical patent/BR0115995A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"FORMULAçãO FARMACêUTICA COMPREENDENDO PIRAZOLO[4,3-d]PIRIMIDINAS E ANTITROMBóTICOS, ANTAGONISTAS DE CáLCIO, PROSTAGLANDINAS OU DERIVADOS DE PROSTAGLANDINA". Preparação farmacêutica compreendendo pelo menos um composto da fórmula (1), na qual R^ 1^, R^ 2^, R^ 3^, R^ 4^ e X são como definidos na reivindicação 1, e sais e/ou solvatos fisiologicamente aceitáveis do mesmo e a) pelo menos um antitrombótico ou b) pelo menos um antagonista de cálcio ou c) pelo menos uma prostaglandina ou derivado de prostaglandina, para a preparação de um medicamento para o tratamento de angina, alta pressão sang³ínea, hipertensão pulmonar, insuficiência cardíaca congestiva (CHF), doença pulmonar obstrutiva crónica (COPD), cor pulmonale, insuficiência dextrocardíaca, aterosclerose, condições de permeabilidade reduzida dos vasos do coração, doenças vasculares periféricas, acidentes vasculares cerebrais, bronquite, asma alérgica, asma crónica, rinite alérgica, glaucoma, síndrome do intestino irritável, tumores, insuficiência renal, cirrose hepática e para o tratamento de distúrbios sexuais femininos.
BR0115995-0A 2000-12-19 2001-11-28 Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina BR0115995A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10063224A DE10063224A1 (de) 2000-12-19 2000-12-19 Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica
DE2000163882 DE10063882A1 (de) 2000-12-21 2000-12-21 Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten
DE2000164993 DE10064993A1 (de) 2000-12-23 2000-12-23 Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate
PCT/EP2001/013916 WO2002049651A1 (de) 2000-12-19 2001-11-28 Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate

Publications (1)

Publication Number Publication Date
BR0115995A true BR0115995A (pt) 2004-01-13

Family

ID=27214208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115995-0A BR0115995A (pt) 2000-12-19 2001-11-28 Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina

Country Status (16)

Country Link
US (1) US20040063730A1 (pt)
EP (1) EP1343506A1 (pt)
JP (1) JP2004516270A (pt)
KR (1) KR20030059349A (pt)
CN (1) CN1481244A (pt)
AR (1) AR035676A1 (pt)
AU (1) AU2002229573A1 (pt)
BR (1) BR0115995A (pt)
CA (1) CA2431077A1 (pt)
CZ (1) CZ20031776A3 (pt)
HU (1) HUP0303315A2 (pt)
MX (1) MXPA03005393A (pt)
NO (1) NO20032773L (pt)
PL (1) PL362513A1 (pt)
SK (1) SK8192003A3 (pt)
WO (1) WO2002049651A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035531A1 (es) * 2001-01-22 2004-06-02 Novartis Ag Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
JP4015176B2 (ja) 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
US7732467B2 (en) * 2003-05-15 2010-06-08 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0509731A (pt) * 2004-04-07 2007-09-25 Pfizer pirazol[4,3-d]pirimidinas
EP2139462B1 (en) * 2007-03-30 2014-01-22 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
ES2449594T3 (es) * 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
HUE047767T2 (hu) * 2008-08-13 2020-05-28 Actelion Pharmaceuticals Ltd Macitentánt tartalmazó terápiás készítmények
CN115282152A (zh) * 2015-01-28 2022-11-04 瑞采生技有限公司 用于增强PPARγ表现及核转位之化合物及其医疗用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10266530B2 (en) 2016-09-09 2019-04-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
IL293326A (en) 2019-11-26 2022-07-01 Ikena Oncology Inc Polymorphic Carbazole History and Uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
JPS5459266A (en) * 1977-10-14 1979-05-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analogs and their preparation
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2672601B1 (fr) * 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
AU734734B2 (en) * 1997-10-28 2001-06-21 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates

Also Published As

Publication number Publication date
KR20030059349A (ko) 2003-07-07
NO20032773D0 (no) 2003-06-18
MXPA03005393A (es) 2003-09-25
AU2002229573A1 (en) 2002-07-01
JP2004516270A (ja) 2004-06-03
US20040063730A1 (en) 2004-04-01
CN1481244A (zh) 2004-03-10
CA2431077A1 (en) 2002-06-27
SK8192003A3 (en) 2003-10-07
HUP0303315A2 (hu) 2004-01-28
NO20032773L (no) 2003-06-18
WO2002049651A1 (de) 2002-06-27
EP1343506A1 (de) 2003-09-17
AR035676A1 (es) 2004-06-23
PL362513A1 (en) 2004-11-02
CZ20031776A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
BR0115995A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
AR032482A1 (es) Uso de tienopirimidinas
BR0116255A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)
WO2003057225A3 (en) Phosphate transport inhibitors
IE902139L (en) Imidazolyl alkenoic acids
RU2002103603A (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
RU2010118022A (ru) Фармацевтическая композиция валсартана
JP2017523219A5 (pt)
KR100979738B1 (ko) 폐질환 치료방법
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
BR0115516A (pt) Composição farmacêutica, e, método para prevenir ou tratar hipertensão
BR0206853A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
CA2770778C (en) Pharmaceutical composition for preventing or treating rheumatoid arthritis containing rebamipide
BR0116849A (pt) Formulações farmacêuticas compreendendo pirazolo[4,3-d]pirimidinas e nitratos ou tienopirimidinas e nitratos
BR0115187A (pt) Uso de pirazolo[4,3-d]pirimidinas
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
BR0116247A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina (2)
KR20200012637A (ko) 에독사반을 포함하는 약학적 제제 및 이의 제조방법
EE03046B1 (et) Angiotensiin II retseptorite antagonistide triasolopürimidiinide derivaadid, nende valmistamise meetod ja ravimvormid
EP0795331B1 (en) Ocular depressor
BR0013957A (pt) Uso de tienopirimidinas
MX2011001887A (es) Derivados de bencil carbonato polimericos.
RU2003108860A (ru) Тиенопиримидины
TH63752A (th) สูตรผสมทางเภสัชกรรมซึ่งประกอบรวมด้วยไพราโซโล[4, 3-d]ไพริมิดีนและสารต้านลิ่มเลือดในหลอดเลือด, แคลเซียมแอนตะกอนิสต์, พรอสตะแกลนดินหรืออนุพันธ์ของพรอสแกลนดิน
US5654339A (en) Use of prostane derivatives of formulate I and II for treatment of chronic polyarthritis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]